



FOR IMMEDIATE RELEASE
NEWS RELEASE
TSX Venture: **AMF**

AMORFIX ANNOUNCES LEADING SENSITIVITY FOR PRION DETECTION IN SPIKED HUMAN BLOOD SAMPLES

TORONTO, ON, June 21, 2006 – Amorfix Life Sciences Ltd. announced today it had completed the analysis of the international reference blinded panels of human blood samples spiked with prions from variant Creutzfeldt-Jakob Disease (vCJD) patients which were provided by the UK government.

“Our excellent results from the blinded panels match our previous internal tests using spiked blood samples. Based on data presented at industry conferences on 4 other laboratories and companies that have completed the blinded panels, we are confident that the company’s EP-CJD™ assay is significantly more sensitive in detecting prions,” said Dr. George Adams, Chief Executive Officer, Amorfix.

“Having superior sensitivity should give Amorfix a competitive advantage in the early detection of prions in blood from donors who are infected but do not yet show symptoms of the disease”, said Dr. Neil Cashman, Chief Scientific Officer, Amorfix. “We look forward to testing blood samples from people who have unfortunately been infected with vCJD and preclinical samples from infected but asymptomatic animals to further validate the utility of the EP-CJD™ to secure the blood transfusion systems worldwide”. Dr. Cashman will be presenting the blinded panel results at the Transmissible Spongiform Encephalopathies conference in Vienna, Austria, on June 28th.

The National vCJD Surveillance Unit (NCJDSU) and the British National Institute for Biological Standards and Controls (NIBSC) direct the international testing program and will publish an independent analysis of all these benchmarking results from those companies who participated. The NCJDSU has blood and tissue samples from approximately 150 people who have been diagnosed with vCJD and subsequently died. The company has sent a request to the British Department of Health, Tissue Management Group to access the final blinded panels containing blood samples from patients with variant CJD, patients with sporadic CJD, patients with other neurological conditions and “normal controls” from blood donors. These results will be used to apply for regulatory approval to market the test in Europe. Since no company, academic or research group has accessed these samples and obtained a CE mark for an assay for vCJD in blood, it is uncertain how many samples are available for testing and exactly how long the process will take. The company is proceeding to mount its assay onto a commercial platform.

Recent evidence has suggested that people may be infected for decades before showing signs of vCJD. The number of people who contracted the disease by consuming BSE-positive beef is unknown and three people have been shown to have been infected through blood transfusion from donors who years later developed symptoms and died from vCJD. Thousands of people who received CJD-positive plasma fractions are currently being monitored to determine how many have been infected. Blood transfusion systems in low-risk countries refuse to take blood from people who have lived in high-risk countries, where BSE-positive cattle were prevalent, to prevent the spread of the disease through blood transfusions. A screening test for vCJD is needed immediately to secure the blood transfusion systems worldwide.

About Amorfix

Amorfix is an emerging theranostics company focused on the diagnosis and treatment of neurodegenerative diseases, where aggregated misfolded proteins (AMPs) are prevalent. These include aggregated misfolded prion protein which makes up “prions,” the infectious agents of the Transmissible Spongiform Encephalopathies (TSE's), such as Bovine Spongiform Encephalopathy (BSE or "mad cow disease") and the human form, variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases such as Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson's Disease (PD). Amorfix was formed to commercialize epitope protection technologies and related discoveries to become the world leader on AMP diseases. The company will use this new knowledge to develop diagnostic kits, therapeutics and preventative therapies for AMP diseases.

For further information, please contact:

Dr. George Adams, President and CEO
Amorfix Life Sciences Ltd.
416-482-3812
info@amorfix.com

James Parsons, CFO
Amorfix Life Sciences Ltd.
416-482-3814

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Actual future results may differ materially from those contemplated. The risks, uncertainties and other factors that could influence the actual results are described in documents filed with regulatory authorities.